Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference

Yu-Ke Fu1†, Bi-Juan Wang1†, Jen-Chih Tseng1, Shih-Han Huang1, Ching-Yu Lin1, Ying-Yu Kuo1, Tzyh-Chyuan Hour2 and Chih-Pin Chuu1,3,4,5*

Abstract

Background: Docetaxel has been approved by USFDA as a first-line treatment for castration-resistant prostate cancer (CRPC) patients. Patients receiving androgen deprivation therapy along with docetaxel result in superior survival, lower serum prostate specific antigen (PSA) level, and better quality of life. However, a significant proportion of these patients ultimately develop resistance to docetaxel within months. Caffeic acid phenethyl ester (CAPE), one of the main bioactive components extracted from the propolis, has been reported to be effective for repressing the tumor growth, the migration and invasion of prostate cancer (PCa) cells, as well as the downstream signaling and stability of androgen receptor (AR). We hence determined if combination treatment of docetaxel with CAPE can suppress the proliferation and the survival of docetaxel-resistant PCa cells.

Methods: We established docetaxel-resistant PC/DX25 and DU/DX50 CRPC cell lines from PC-3 and DU-145 human PCa cells, respectively. Proliferation assay, MTT assay, flow cytometry with Annexin V staining, Comet Assay, and nude mice xenograft model were applied to determine the effects of combination treatment on cell proliferation and survival of the docetaxel-resistant PCa cells. Micro-Western Array (MWA) and qRT-PCR were used to investigate the molecular mechanism lying underneath.

Results: Combination treatment effectively suppressed the proliferation, survival and tumor growth of docetaxel-resistant PCa cells both in vitro and in nude mice. Comet assay and flow cytometry indicated that combination treatment induced apoptosis in docetaxel-resistant PCa cells. MWA and Western blotting assay revealed that combination treatment suppressed protein expression of Bcl-2, AKT2, c-Myc, apoptosis and caspase activation inhibitor (AVEN), pyruvate kinase M2 (PKM2) but increased protein expression of Bax, caspase 3, cytochrome c, glucose-6-phosphate...
Androgen deprivation therapy (ADT) is the primary treatment for metastatic prostate cancer (PCa). However, most PCa patients receiving ADT develop recurrent castration-resistant prostate cancer (CRPC) within 3 years, with a median overall survival time of 1–2 years [1, 2]. Docetaxel is a commonly used cancer chemotherapy drug which belongs to the taxane class. Docetaxel is a synthetic analogue of paclitaxel, an extract from the bark of the rare *Taxus brevifolia* [3]. Docetaxel binds to the β-tubulin subunit of the microtubules, stabilizes the microtubule assembly, and prevents the depolymerization and disassembly of microtubule [4]. As a result, docetaxel reduces free tubulin in cytoplasm, inhibits the mitotic cell division, and suppresses the proliferation and survival of cancer cells [4]. Treatment with docetaxel plus prednisone has been approved by USFDA as a first-line treatment for CRPC patients. Patients with metastatic hormone-sensitive PCa receiving ADT plus docetaxel had a medium overall survival of 57.6 months, which was 13.6 months longer than that of patients receiving ADT alone [5]. Treatment with docetaxel and prednisone or docetaxel and estramustine for metastatic CRPC patients results in superior survival, improved rates of response in terms of pain, lower serum PSA level, and better quality of life as compared to treatment with mitoxantrone plus prednisone [6, 7]. However, a significant proportion of PCa patients receiving docetaxel-based therapy ultimately develop drug resistance [8, 9]. Several mechanisms have been reported to contribute to the development of docetaxel-resistant, including mutations in microtubule, evolution of cancer stem cells, elevation of Multi-Drug Resistance (MDR) family of efflux transporters, re-activation of androgen receptor (AR) signaling, upregulation of PI3K-AKT signaling [8], as well as dysregulation of PPARα (peroxisome proliferator-activated receptor α) signaling and CDH1 gene [10].

We previously reported that CAPE treatment suppressed the cell proliferation of both androgen-dependent and androgen-independent PCa cells via inhibition of AKT signaling and c-Myc [13–15]. We also discovered that CAPE treatment suppressed the phosphorylation of Ser81 and Ser213 on AR, therefore decreased the stability of AR and induced degradation of AR protein in PCa cells [16]. As re-activation of AR signaling and upregulation of AKT signaling have been reported to promote the development of resistance to docetaxel in CRPC, we investigated if combination treatment of docetaxel and CAPE can suppress the proliferation and survival of docetaxel-resistance PCa cells.

**Materials and methods**

**Chemicals**

Caffeic acid phenethyl ester (CAPE) was purchased from Sigma-Aldrich (St. Louis, MO, U.S.A.), while docetaxel was purchased from Cayman Chemicals (Ann Arbor, MI, U.S.A.).

**Cell culture**

PC-3 and DU-145 cells were purchased from ATCC. Docetaxel-resistant sublines PC/DX25 and DU/DX50 sublines were developed by chronically exposing PC-3 and DU-145 cells to progressively increased concentrations of docetaxel. PC-3 and DU-145 cells were maintained in RPMI-1640 medium containing 10% FBS, penicillin (100 U/ml), and streptomycin (100 μg/ml) at 37°C with 5% CO2. PC/DX and DU/DX cells were maintained with 25 nM and 50 nM docetaxel, respectively.

**Cell proliferation assay**

PC/DX25 and DU/DX50 cells were seeded at a density of 3 × 103 cells/well in 96-well plates with 100 μl RPMI-1640 medium containing 10% FBS and increasing concentration of docetaxel and CAPE for 96 h. Relative cell number was analyzed by measuring the DNA content of cell lysates with Hoechst dye 33,258-based 96-well proliferation assay (Sigma, St. Louis, MO, USA) as described previously [17]. All readouts were normalized to the average.
of the control condition in each individual experiment. The experiment was repeated at least eight times.

**Cell viability assay**
PC/DX25 and DU/DX50 cells were seeded at a density of $5 \times 10^3$ cells per well in a 96-well plate (BD Bioscience). After 24 h, the cells were treated with increasing concentrations of docetaxel and CAPE for 96 h. Cell viability was assessed by an MTT (3,4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide) assay as previously described [15]. The amount of formazan was determined by measuring the absorbance at 560 nm using a Tecan GENios™ plate reader (Tecan group Ltd, Männedorf, Switzerland). All results were normalized to the average of the control condition in each individual experiment. All experiments were repeated at least three times.

**Comet assay**
PC/DX25 and DU/DX50 cells were seeded overnight in a 6 cm dish with a density of $1 \times 10^5$ cells per well in 5 ml of culture medium. On the second day, cells were treated with docetaxel (25 nM for PC/DX25 and 50 nM for DU/DX50) and increasing concentration of CAPE for additional 48 h. Comet assay was performed with OxiSelect™ Comet Assay Kit (Cell Biolabs, San Diego, CA, USA) according to the manufacturer’s instruction. All experiments were repeated three times.

**Xenograft experiment in nude mice**
The animal protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of NHRI in Taiwan (NHRI-IACUC-100105). BALB/c nude mice of 4–5 weeks old were purchased from BioLASCO (Taipei, Taiwan). PC/DX25 cells mixed with Matrigel (BD Biosciences) and were injected subcutaneously into both flanks ($1 \times 10^6$ cells/side) of the mice. Mice were then randomly separated into the control and the combination treatment group, each with 5 mice. There were 5 tumors developed in the control group and 4 tumors developed in the combination treatment group. The control group received docetaxel (5 mg/kg) via i.p. twice per week while the combination treatment group received docetaxel (5 mg/kg) plus CAPE (10 mg/kg) via i.p. injection twice per week. Tumor growth was monitored by measuring the length and width of the tumor by absolute digimatic caliper. The tumor sizes were calculated using the following formula $= \text{length} \times \text{width} \times \text{height} \times 0.52$. Body weight and tumor size of the mice were monitored three times a week.

**Flow cytometry**
PC/DX25 cells were seeded in a 6 well-plate with a density of $2 \times 10^5$ cells per well in 5 ml of culture medium for 24 h. Cells were then treated with 25 nM docetaxel and increasing concentrations of CAPE for 48 h. Flow cytometry was performed as previously described [18]. All experiments were repeated three times.

**Western blotting analysis and Micro-Western Array**
Western blotting assay was performed as previously described [16]. All the antibodies used in present study were listed in Additional file 1: Table S1. Anti-rabbit and anti-mouse IgG secondary antibodies purchased from Santa Cruz Biotechnology. Intensity of bands for different proteins were quantified with Image J software after EPSON stylus TX130 scanning. Micro-Western Array (MWA) were performed as previously described [13]. Blots were analyzed by Odyssey analysis software (Li-Cor Biosciences, USA). Heatmaps were created by using PermutMatrix software (LIRMM). Antibody information was listed in Additional file 1: Table S1.

**Immunohistochemistry**
Paraffin embedded tissue sections were derived from xenografts in nude mice mentioned above. The immunohistochemistry staining was performed as previously described [19]. All of antibodies used were listed in Additional file 1: Table S1.

**Data analysis**
Data are presented as the mean ± SD of at least three experiments. Student’s T test (two-tailed, unpaired) was used to evaluate the statistical significance of results from proliferation assay experiments.

**Results**
Combination treatment of docetaxel with CAPE suppresses the proliferation and the survival of docetaxel-resistant PCa cell lines
Docetaxel-resistant PC/DX25 and DU/DX50 cell lines were developed by chronically exposing PC-3 and DU-145 cells to progressively increased concentrations of docetaxel. The initial concentration of docetaxel being added to the culture medium was 5 nM for both PC-3 and DU-145 cells. The survived cells were then gradually being treated with increasing concentration of docetaxel. The final concentration of docetaxel in culture medium for maintaining the docetaxel-resistant PC-3 and DU-145 cells were 25 nM and 50 nM docetaxel, respectively. These drug-resistant PCa cells were named as PC/DX25 and DU/DX50,
respectively. Hoechst dye 33,258-based proliferation assay and MTT assay were used to examine the effects of docetaxel and CAPE on cell proliferation and survival of PC/DX25 cells and DU/DX50 cells. PC/DX25 cells were treated with increasing concentration of docetaxel (25–250 nM) (Fig. 1A) or CAPE (0–40 μM) (Fig. 1B) for 96 h. IC_{50} of docetaxel and CAPE to suppress PC/DX25 cells is 316.4 nM and 15.7 μM, respectively. We then examined the effects of combination treatment of docetaxel with CAPE on proliferation of PC/DX25 cells. We chose to use 20 μM CAPE, which is close to the IC_{50} of CAPE for PC/DX25 cells. When 20 μM CAPE was used in combination with docetaxel, the IC_{50} of docetaxel to suppress the DU/DX50 cells reduced to 35.0 nM (Fig. 1C).

MTT assay was performed to examine the effects of combination treatment on the survival of PC/DX25 and DU/DX50 cells. The IC_{50} of docetaxel and CAPE to suppress the survival of PC/DX25 cells was 310.9 nM and 20.3 μM, respectively (Fig. 2A, B). The IC_{50} of docetaxel to suppress the survival of DU/DX50 cells is 278.0 nM and 18.5 μM, respectively (Fig. 2D, E). The IC_{50} of docetaxel to suppress the survival of DU/DX50 cells reduced to 29.7 nM (Fig. 2F) when docetaxel was used in combination with 20 μM CAPE, which is close to the IC_{50} of CAPE for DU/DX50 cells.

Combination treatment suppresses the tumor growth of docetaxel-resistant PC/DX25 xenografts in nude mice
To examine if combination treatment can suppress tumor growth of docetaxel-resistant PCa cells in vivo, we inoculated PC/DX25 cells into both flanks of nude mice. The PC/DX25 xenografts continued growing in control group (receiving only docetaxel via i.p. injection, twice per
Combination treatment of docetaxel plus CAPE (both via i.p. injection, twice per week) effectively suppressed the tumor growth of PC/DX25 tumors (Fig. 3A–D). Body weight of nude mice in both groups was not affected by docetaxel or CAPE treatment (Fig. 3B). During the dissecting of the tumors, we observed that combination treatment reduced the number of blood vessels around the tumors as compared to control group.

**Combination treatment induces apoptosis in the docetaxel-resistant PCa cells**

As we observed that combination treatment decreased the survival of PC/DX25 and DU/DX50 cells, we determined if combination treatment induced apoptosis in these docetaxel-resistant PCa cells. Comet assay (Fig. 4A–D) as well as the flow cytometry analysis of Annexin V and PI (propidium iodide) staining (Fig. 5) indicated that combination treatment dose-dependently induced apoptosis in PC/DX25 and DU/DX50 cells.

**Combination treatment affects the expression of signaling proteins involved in cell survival and metabolism**

To elucidate the molecular mechanisms how combination treatment suppresses the proliferation and survival of docetaxel-resistant PCa cells, we performed high-throughput Micro-Western Array (MWA) (Fig. 6A) to evaluate the expression level of 96 proteins involved in cell cycle regulation, apoptosis, AKT signaling, cholesterol efflux and metabolism. These signaling pathways are essential for the regulation of cell proliferation and survival in advanced PCa cells. Combination treatment of docetaxel and CAPE increased the protein abundance of G6PD (glucose-6-phosphate dehydrogenase), cytochrome c, phospho-GSK3β Ser9, AGK (acylglycerol kinase), GSK3α (Glycogen Synthase Kinase-3α), cleaved caspase 3 but decreased protein abundance of cyclin D1, AVEN (apoptosis and caspase activation inhibitor), AKT2, COX2, PKM2 (Pyruvate Kinase M2), and cyclin B1 (Fig. 6B).
Western blotting revealed that combination treatment increased the protein expression level of PARP (poly ADP-ribose polymerase), cleaved PARP, Bax, cleaved caspase 3, cleaved caspase 9, and cytochrome c but decreased the protein abundance of Bcl-2, cyclin D1, and AVEN in PC/DX25 and DU/DX50 cells (Fig. 7A–D). These observations confirmed that combination treatment induced apoptotic proteins in docetaxel-resistant PCa cells. Similarly, immunohistochemistry staining revealed that combination treatment increased the protein expression level of Bax and cleaved caspase 3, but decreased that of Ki67, Bcl-2, and CD31 in PC/DX25 tumors (Fig. 8A, B).

**Fig. 3** The suppressive effects of the combination treatment using docetaxel and CAPE on PC/DX25 xenografts in nude mice. A Docetaxel-resistant PC/DX25 cells were injected subcutaneously on both flanks (1 × 10⁶ cells/side) of the nude mice. Tumors were allowed to grow for 2 weeks to reach an average volume larger than 100 mm³. Mice were randomly separated into control group (receiving 5 mg/kg docetaxel twice per week via i.p. injection) or combination treatment group (receiving 5 mg/kg docetaxel plus 10 mg/kg CAPE, both twice per week via i.p. injection). Tumor growth was monitored for 29 days before mice were sacrificed. Tumors were measured twice per week with absolute digimatic calipers. Tumor volume was calculated with the formula volume = length x width x height x 0.52. B Body weight of mice in control group and combination treatment group was measured at the same time as tumor volume measurement. The body weight in each group was shown as mean ± standard error. C Photographs of xenografts in control group (docetaxel treatment only) and in combination treatment group (docetaxel plus CAPE). D Photographs of mice being dissected were shown for images of blood vessels nearby tumors. All data were percentage of that. Results present as mean ± standard error (n ≥ 3; **p < 0.001; ***p < 0.0001 vs. control).

Overexpression of Bcl-2 increases the cell proliferation of docetaxel-resistant PCa cells under combination treatment

As we demonstrated that combination treatment lessened the protein abundance of Bcl-2 in PCa cells both in vitro (Figs. 6, 7) and in animal model (Fig. 8), we determined if Bcl-2 is one of the main targets for combination treatment. We used DU/DX50 cells for Bcl-2 overexpression as the combination treatment caused a more significant reduction of Bcl-2 in DU/DX50 cells (Fig. 7B) as compared to that in PC/DX25 cells (Fig. 7A). Overexpression of Bcl-2 in DU/DX50 cells (Fig. 9A) enhanced the cell proliferation of DU/DX50 cells under combination
treatment (Fig. 9B). There results implied that the combination treatment suppressed the proliferation and survival of docetaxel-resistant PCa cells, at least partially, via the inhibition of Bcl-2.

Combination treatment affects the expression of metabolic genes

MWA analysis suggested that the combination treatment altered the expression of proteins involved in metabolism regulation (Fig. 6). Western blotting assay revealed that CAPE dose-dependently increased protein abundance of G6PD but decreased the protein expression of AKT2 and c-Myc proteins (Fig. 10A). These proteins are important in the regulation of cancer metabolism. We therefore performed qRT-PCR to examine the effects of combination treatment on metabolic genes involved in glycolysis, tricarboxylic acid cycle (TCA) cycle, glutamine metabolism, and nucleotide metabolism (Additional file 2: Fig. S1 and Additional file 3: Fig. S2). Combination treatment increased the gene expression of GGT1, GLS, G6PD, IDH2, NUJD9, TALD01, PGLS, GPI, ALDOA, PKM2, PGK1, and KGDH but decreased the gene expression of DHCR24, LSS and ENO1 in PC/DX25 cells (Fig. 10B). Similarly, the combination treatment increased the gene expression of GGT1, IDH2, GAPDH, MDH, PGLS, G6PD, GLS, ALDOA, GPI, HK2, NUJD9, and PKM2 but decreased the gene expression of DHCR24 and LSS in DU/DX50 cells (Fig. 10C). These observations indicated that the combination treatment interfered metabolism in PC/DX25 and DU/DX50 cells.

Discussion

Docetaxel plus prednisone has been approved by USFDA as a first-line treatment for metastatic CRPC patients. Patients receiving ADT plus docetaxel have longer survival, lower serum PSA level, and better quality of life [5–7, 9]. A significant proportion of CRPC patients who initially respond to docetaxel therapy ultimately develop
drug resistance [8, 9]. Therefore, novel therapeutic agents are in need for treating docetaxel-resistant PCa. In this study, we demonstrated that the combination treatment of docetaxel and CAPE can effectively suppress the proliferation and survival of docetaxel-resistant PC/DX25 and DU/DX50 PCa cells both in vitro and in nude mice xenograft model. We developed docetaxel-resistant PC/DX25 and DU/DX50 cell lines by chronically exposing PC-3 and DU-145 cells to progressively increased concentrations of docetaxel, with an initial concentration of 5 nM docetaxel to a final concentration of 25 nM and 50 nM docetaxel for PC-3 and DU-145 cells, respectively. Previous clinical study reported that patients receiving docetaxel (35 mg/m²) weekly via infusion showed a half-life of docetaxel clearance to be approximately 17 h, and the study demonstrated an average concentration of plasma docetaxel on day 8 after docetaxel treatment to be approximately 1.08 ± 0.51 nM [20]. According to the proliferation assay, the IC₅₀ for docetaxel to suppress the proliferation of docetaxel-resistant PC/DX25 and DU/DX50 cells was 316.4 nM and 395.3 nM, respectively. In addition, PC/DX25 and DU/DX50 cells were cultured in 25 nM and 50 nM docetaxel, respectively. The concentration of docetaxel we used for establishing docetaxel-resistant PCa cell lines, 5–50 nM, reflected the concentration of docetaxel in patient serum. The drug-resistance of the PCa cell lines we developed may reflect the docetaxel-resistant prostate tumors in patients. In our combination treatment experiments, we used 20 μM CAPE for both PC/DX25 and DU/DX50 cells.

Fig. 5 Combination treatment of docetaxel along with CAPE induced apoptosis in PC/DX25 cells as determined by Annexin V staining. PC/DX25 cells were treated with 25 nM docetaxel in combination with or without 10 μM CAPE for 24 or 48 h. Cells were harvested and stained with propidium iodide dye and Annexin V for flow cytometry analysis of apoptosis.
The achievable concentration of CAPE in human serum is approximately 17 μM [21]. As a result, the dosage of CAPE being used in our combination treatment study is achievable in clinical treatment.

Bcl-2 is an anti-apoptotic oncoprotein. Elevation of Bcl-2 is observed in CRPC tumors [22] and up-regulation of Bcl-2 is essential for the development of CRPC [23]. It has been reported that TGF-β promotes resistance to docetaxel in PC-3 and DU-145 cells via acetylating KLF5 and inducing Bcl-2 [24], suggesting that Bcl-2 plays an essential role in the development of docetaxel resistance in PCa cells. Expression of Bcl-2 protein level in tumors is a predictive marker of outcome for CRPC patients receiving taxane-based chemotherapy [25]. Combination therapy of a phosphorothioate antisense oligonucleotide targeting Bcl-2 with docetaxel increased the overall survival of CRPC patients [26]. The subpopulation of CRPC cells which acquire docetaxel-resistance were found

| marker | CAPE (μM) |
|--------|-----------|
| 0      | 10        | 20        | 40        |

**Fig. 6** Micro-Western Array (MWA) analysis of signaling proteins affected by combination treatment in PC/DX25 cells. A Images of the two MWA blots analyzing the changes of expression level of signaling proteins involved in regulation of cell proliferation, survival, and metabolism in PC/DX25 cells treated with 25 nM docetaxel and increasing concentration (0, 10, 20, 40 μM) of CAPE for 96 h. Each well was loaded with two protein markers and triplicates of PC/DX25 cell samples. The names of different antibodies being used were shown at the bottom right corner of each well on the two blots. B Expression of proteins with changes larger than 1.5-fold increase or decrease was demonstrated with a heatmap using log2 value. Red color indicated an increase of protein abundance, while blue color indicated a decrease of protein abundance.
Fig. 7  Combination treatment affected the expression of apoptosis regulatory proteins in PC/DX25 and DU/DX50 cells. PC/DX25 (A) and DU/DX50 (B) cells were treated with 25 nM or 50 nM docetaxel, respectively, in combination with 0, 20, or 40 μM CAPE for 96 h. Protein expression of PARP, Bcl-2, Bax, caspase 3, cleaved caspase 3, caspase 9, cleaved caspase 9, caspase 8, cyclin D1, AVEN, and cytochrome c was examined by Western blotting. The β-actin was used as loading control. Quantification for protein expression level of important regulatory proteins from at least three different experiments was shown for PC/DX24 (C) and DU/DX50 (D) cells.

Fig. 8  Combination treatment affected the expression of proteins regulating cell proliferation, apoptosis, and angiogenesis in PC/DX25 xenografts. A Protein expression level of Ki67, Bcl-2, Bax, cleaved caspase-3, and CD31 in prostate tissues of control group mice (docetaxel treatment plus control vehicle) or combination treatment group mice (docetaxel treatment plus CAPE) carrying PC/DX25 xenografts was examined by immunohistochemistry staining. The magnification for images is 400X. Relative protein expression intensity was shown under each IHC image. B The relative protein expression intensity for Ki67, Bcl-2, Bax, cleaved caspase-3, and CD31 in prostate tissues of control group mice vs. combination treatment group mice was shown as heatmap using log2 value.
to lack differentiation markers and HLA class I (HLAI) antigens, while these cells exhibited elevated level of the Notch and Hedgehog signaling pathways [27]. Inhibition of Notch and Hedgehog signaling via suppression of the AKT signaling and Bcl-2 depleted the docetaxel-resistant cell population in CRPC tumors [27]. CAPE treatment has been shown to increase docetaxel and paclitaxel potency in PC-3, DU-145 and LNCaP cells [28]. In our current study, combination treatment of docetaxel and CAPE significantly reduced the protein expression of Bcl-2 in docetaxel-resistant PCa cells both in cell culture and xenograft tumors. We demonstrated that overexpression of Bcl-2 increased the cell proliferation of docetaxel-resistant PCa cells under combination treatment,
suggesting that combination treatment induced apoptosis and growth inhibition in docetaxel-resistant PCa cells, at least partially, via the suppression of Bcl-2. In addition, the suppression of AKT2 and c-Myc by combination treatment (Fig. 10A) will also contribute to the inhibition of proliferation and survival of docetaxel-resistant PCa cells.

DHCR24 gene encodes the protein 3β-dehydrocholesterol-Δ24-reductase, which is a key enzyme in the cholesterol synthesis Bloch and Kandutsch-Russell pathway [29]. DHCR24 catalyzes desmosterol to cholesterol in Bloch pathway and catalyzes lanosterol to 24,25-dihydrolanosterol in the Kandutsch-Russell pathway [29]. Suppression of DHCR24-mediated cholesterol biosynthesis and lipid rafts formation results in inhibition of tumor growth and invasion of hepatocellular carcinoma [30]. DHCR24 promotes the proliferation of bladder cancer cells and bladder cancer patients have better clinical outcomes with lower DHCR24 expression in tumors [31]. Additionally, DHCR24 promotes the cell proliferation of cancer stem cells of breast cancer via regulation of Hedgehog pathway [29]. DHCR24 also aggravates the invasion and progesterone resistance in endometrial cancer cells [32]. Activation of de novo cholesterogenesis is essential for the development and progression of PCa. Suppression of cholesterol biosynthesis has been shown to reduce the survival and tumor growth of enzalutamide-resistant CRPC cells [33]. Expression of DHCR24 is higher in PCa tumors as compared to adjacent normal prostate tissues and the expression of DHCR24 is regulated by androgen in prostate tumors [34]. Lanosterol synthase (LSS) catalyzes the conversion of 2,3-oxidosqualene to lanosterol, the first sterol in the cholesterol biosynthetic pathway [35]. Inhibition of LSS suppresses the proliferation of glioma cells [36]. In our current study, the repression of DHCR24 and LSS by combination treatment in both PC/DX25 and DU/DX50 cells may interfere the cholesterol biosynthesis and therefore induce growth inhibition in these docetaxel-resistant PCa cells.

Interestingly, we observed that the combination treatment activated several genes involved in pentose phosphate pathway, tricarboxylic acid cycle (TCA) cycle, and glutamine metabolism. Glucose-6-phosphate dehydrogenase (G6PD) is the first and rate-limiting enzyme of the pentose phosphate pathway (PPP), which catalyzes the oxidation of glucose-6-phosphate and eventually produces ribose and NADPH via the pentose phosphate pathway (PPP). Both ribose and NADPH are essential for the synthesis of cellular building materials, such as nucleic and fatty acids. G6PD is one of the major enzymes involved in cell survival following redox imbalance and it plays an essential role to protect cells from stress-induced apoptosis [37]. 6-Phosphogluconolactonase (PGLS) catalyzes the second step of the PPP pathway via hydrolyzing 6-phosphogluconolactone to 6-phosphogluconic acid [38]. Gamma-glutamyltransferase 1 (GGT1) catalyzes the transfer of the glutamyl moiety of glutathione to various amino acids [39]. Glutaminase (GLS) converts glutamine to glutamate [40]. Isocitrate dehydrogenases 2 (IDH2) catalyzes the oxidative decarboxylation of isocitrate into α-ketoglutarate in TCA cycle [41]. Acylglycerol kinase (AGK) is a multi-substrate lipid kinase which catalyzes the phosphorylation of acylglycerols to generate lysophosphatidic acid (LPA) [42]. AGK is reported to inhibit apoptosis via activation of the NF-κB signaling in hepatocellular carcinoma [42]. It is possible that the docetaxel-resistant PCa cells try to overcome the stress of combination treatment and manage to survive via inducing a compensatory-induction of G6PD, PGLS, GGT1, GLS, IDH2, and AGK for activation of glycolysis, TCA cycle, and lipid metabolism. The fact that the docetaxel-resistant PCa cells went apoptosis 96 h after the treatment of docetaxel plus CAPE suggested that the compensatory-induction of metabolic genes cannot rescue the cancer cells.

CD31 (also known as Platelet and Endothelial Cell Adhesion Molecule 1, PECA1) is highly expressed on the surface of endothelial cells and is a well-established marker for angiogenesis [43]. We observed that combination treatment decreased the protein abundance of CD31 in PC/DX25 xenografts and reduced the blood vessels around the tumors, suggesting that combination treatment may suppress the angiogenesis of docetaxel-resistant prostate tumors.

Conclusions
In conclusion, our current study suggested that the combination treatment of docetaxel with CAPE can restore the sensitivity of docetaxel-resistant PCa cells to docetaxel treatment. Combined treatment of CAPE and docetaxel effectively suppressed the proliferation and survival of docetaxel-resistant PCa cells via inhibition of Bcl-2, c-Myc, AKT2 and induction of metabolism interference. Combination treatment of CAPE and docetaxel may be beneficial for PCa patient acquired docetaxel resistance.

Abbreviations
AKT: Protein kinase B; ADT: Androgen deprivation therapy; AGK: Acylglycerol kinase; AR: Androgen receptor; AVEN: Apoptosis and caspase activation inhibitor; CAPE: Caffeic acid phenethyl ester; CRPC: Castration-resistant prostate cancer; DMEM: Dulbecco’s Modified Eagle Medium; FBS: Fetal bovine serum; G6PD: Glucose-6-phosphate dehydrogenase; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; GGT1: Gamma-glutamyltransferase 1; GLS: Glutaminase; G6K3z: Glycogen synthase kinase-3z; IDH2: Isocitrate dehydrogenase;
We thank the support from the Micro-Western Array core facility of NHRI.

**Acknowledgements**

The data presented in the study are included in the article and supplementary material. All authors read and approved the final manuscript.

**Availability of data and materials**

The supplementary file contains all the materials. Micro-Western blotting and IHC staining assay were listed for the name of antibody and the company information.

**Additional file 1: Table S1.** All antibodies used in Western blotting.

**Additional file 2: Figure S1.** Effects of combination treatment on metabolic genes in PC/DX25 cells. Effects of combination treatment on metabolic genes in PC/DX25 cells treated with 50 nM docetaxel plus increasing concentration of CAPE (0, 10, 20, 40 μM) for 48 h were examined by qRT-PCR.

**Additional file 3: Figure S5.** Effects of combination treatment on metabolic genes in PC/DX25 cells. Effects of combination treatment on metabolic genes in DU/DX50 cells treated with 50 nM docetaxel plus increasing concentration of CAPE (0, 10, 20, 40 μM) for 48 h were examined by qRT-PCR.

**Funding**

This study was supported by MOST 109-2320-B-400-004-MY3 (Ministry of Science and Technology) and intramural research funding from NHRI (National Health Research Institutes) for CPC in Taiwan. YKK is supported by MOST 109-2811-B-400-514. The funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

**Availability of data and materials**

The data presented in the study are included in the article and supplementary material.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Institute of Cellular and System Medicine, National Health Research Institutes, No. 33, Keyan Road, Zhunan Town 35053, Miaoli County, Taiwan. 2. Department of Biochemistry, Kaohsiung Medical University, Kaohsiung, Taiwan. 3. Graduate Program for Aging and Graduate Institute of Basic Research Sciences, China Medical University, Taichung, Taiwan. 4. Biotechnology Center, National Chung Hsing University, Taichung City, Taiwan. 5. Department of Life Sciences, National Central University, Taooyuan City, Taiwan.

**References**

1. Hellersiedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002;52(3):154–79.

2. Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, Lin CY, Huo C, Su LC. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J Biomed Sci. 2011;18:63.

3. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999;36(2):99–114.

4. Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(7):2513–31.

5. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger MA, Wong YN, Hahn N, Kohli M, Cooney MM, Dreirer R, Vogelzang NJ, Picus J, Shevlin M, Hussain MA, Garcia JA, DiPaola RS. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.

6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, Investigators TAX. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

7. Petroly DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.

8. Bumbaca B, Li W. Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies. Acta Pharm Sin B. 2012;11(2):329–39.

9. Hwang C. Overcoming docetaxel resistance in prostate cancer: a perspective review. Ther Adv Med Oncol. 2012;6(6):329–40.

10. Marin-Aguilera M, Codony-Servat J, Kaliko SG, Fernandez PL, Bermudo LT, Kung HJ, Wang HD, Chuu CP. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells. PLoS ONE. 2012;7(2):e31286.

11. Bhimani R, Sallie W, Gruber D, Frenkel K. Inhibition of oxidative stress in HeLa cells by chemopreventive agents. Cancer Res. 1993;53(19):4528–33.

12. Natarajan K, Singh S, Burke TR Jr, Gruber D, Agharwal BB. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci USA. 1996;93(17):9090–5.

13. Chuu CP, Lin HP, Ciaccio MF, Kokontis JM, Hause JR Jr, Hiipakka RA, Liao S, Jones RB. Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signal-n ing networks. Cancer Prev Res (Phila). 2012;5(5):788–97.

14. Lin HP, Jiang SS, Chuu CP. Caffeic acid phenethyl ester causes p21 induction, Akt signaling reduction, and growth inhibition in PC-3 human prostate cancer cells. PLoS ONE. 2012;7(2):e31286.

15. Lin HP, Lin CY, Huo C, Hsiao PH, Su LC, Jiang SS, Chan TM, Chang CH, Chen LT, Kung HJ, Wang HD, Chuu CP. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget. 2015;6(9):7684–707.

16. Kuo YY, Huo C, Lin CY, Lin HP, Liu JS, Wang WC, Chang CR, Chuu CP. Caffeic acid phenethyl ester suppresses androgen receptor signaling and stability via inhibition of phosphorylation on Ser81 and Ser213. Cell Commun Signal. 2019;17(1):100.

17. Chuu CP, Chen RT, Kokontis JM, Hiipakka RA, Liao S. Suppression of androgen receptor signaling and prostate specific antigen expression by (−)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett. 2009;275(1):86–92.
18. Lin CY, Hugo C, Kuo LK, Hiipakka RA, Jones RB, Lin HP, Hung Y, Su LC, Tseng JC, Kuo YY, Wang YL, Fukui Y, Kao YH, Kokoint JM, Yeh CC, Chen L, Yang SD, Fu HH, Chen YW, Tsai KK, Chang YJ, Chou CP. Cholesterol-3beta, Salpha, 3beta-tio suppresses proliferation, migration, and invasion of human prostate cancer cells. PLoS ONE. 2013;8(6):e65734.

19. Tseng XC, Huang SH, Lin CY, Wang BJ, Huang SF, Shen YY, Chou CP. ROR2 suppresses metastasis of prostate cancer via regulation of miR-199a-5p-PIAS3-AT2 signaling axis. Cell Death Dis. 2020;11(5):376.

20. Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res. 2004;10(6):1976–83.

21. Celli N, Draquani LK, Murzilli S, Pagliani T, Poggi A. In vitro and in vivo stability of caffeic acid phenethyl ester, a bioactive compound of propolis. J Agric Food Chem. 2007;55(9):3398–407.

22. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992;52(24):6940–4.

23. Lin Y, Fukuchi J, Hiipakka RA, Kokoint JM, Xiang J. Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage. Cell Res. 2007;17(6):531–6.

24. Li Y, Zhang B, Xiang L, Xia S, Kucuk O, Deng X, Boise LH, Dong JT. TGF-beta causes Doxorubicin resistance in Prostate cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. Theranostics. 2020;10(17):7566–70.

25. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, Igawa M. Suppression of acquired docetaxel resistance in prostate cancer through the induction of miR-199a-5p-PIAS3-AT2. Cell Death Dis. 2020;11(5):376.

26. Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Sparreboom A, Carducci MA. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res. 2004;10(6):1976–83.

27. Thoma R, Schulz-Gasch T, D’Arcy B, Benz J, Abej J, Dehmlow H, Hennig M, Stihle M, Ruf A. Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase. Nature. 2004;432(7013):118–22.

28. Phillips RE, Yang Y, Smith RC, Thompson BM, Yamasaki T, Soto-Feliciano YM, Funato K, Liang Y, Garcia-Bernardez J, Wang X, Garcia BA, Yamasaki K, McDonald JG, Bisoy K, Tabar V, Allis CD. Target identification reveals lanosterol synthase as a vulnerability in glioma. Proc Natl Acad Sci USA. 2019;116(16):7957–62.

29. Fico A, Paglialunga F, Ciglinano L, Abrescia P, Verde P, Martini G, Iaccarino I, Filosa S. Glucose-6-phosphate dehydrogenase plays a crucial role in protection from redox-stress-induced apoptosis. Cell Death Differ. 2004;11(8):823–31.

30. Collard F, Collet JF, Gerin J, Veiga-da-Cunha M, Van Schaftingen E. Identification of the cDNA encoding human 6-phosphogluconolactonase, the enzyme catalyzing the second step of the pentose phosphate pathway (1). FEMS Lett. 1999;459(2):223–6.

31. Wickham S, West MB, Cook PF, Hanigan MH. Gamma-glutamyl compounds: substrate specificity of gamma-glutamyl transpeptidase enzymes. Anal Biochem. 2011;414(2):208–14.

32. Katt WP, Lukay MJ, Cerione RA. A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis. Future Med Chem. 2017;9(2):223–43.

33. Martinez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun. 2020;11(1):120.

34. Cui Y, Lin C, Wu Z, Liu A, Zhang X, Zhu J, Wu G, Wu J, Li M, Li J, Song L. AGK enhances angiogenesis and inhibits apoptosis via activation of the NF-kappaB signaling pathway in hepatocellular carcinoma. Oncotarget. 2014;5(23):12057–69.

35. Delisser HM, Christoffidou-Solomidou M, Stineter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, Garlanda C, Merovin JR, Madi JA, Alбедa SM. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol. 1997;151(3):671–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.